Oculis Holding AG (OCS) Non-Current Debt (2021 - 2022)
Oculis Holding AG (OCS) recorded quarterly Non-Current Debt of $127.1 million in Q4 2022, up 3.26% quarter-over-quarter from $123.1 million in Q4 2021, and up 3.26% on a YoY basis from $123.1 million in Q4 2021.
Oculis Holding AG (OCS) Non-Current Debt (2021 - 2022) Analysis & Trends
Oculis Holding AG's Non-Current Debt history runs 2 years deep, the most recent figure standing at $127.1 million for Q4 2022.
- In Q4 2022, Non-Current Debt rose 3.26% year-over-year to $127.1 million; the TTM figure through Dec 2022 stood at $127.1 million (up 3.26% YoY), while the FY2022 annual figure was $127.1 million, up 3.26% from the prior year.
- Non-Current Debt was $127.1 million for Q4 2022 at Oculis Holding AG, up from $123.1 million in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $127.1 million in Q4 2022 to a low of $123.1 million in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 319.10 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | - |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | Oculis Holding AG | 8.23 Bn | 7.92 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 127.10 Mn |
| Dec 31, 2022 | 127.10 Mn |
| Dec 31, 2021 | 123.09 Mn |
| Dec 31, 2021 | 123.09 Mn |